QuidelOrtho Corporation (NASDAQ:QDEL – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $13.79, but opened at $17.00. QuidelOrtho shares last traded at $18.8740, with a volume of 1,430,590 shares changing hands.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on QDEL. Jefferies Financial Group lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating and cut their target price for the stock from $35.00 to $12.50 in a research report on Thursday, May 7th. Zacks Research raised shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Wall Street Zen upgraded shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research note on Sunday. UBS Group reaffirmed a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $14.88.
Read Our Latest Stock Report on QuidelOrtho
QuidelOrtho Price Performance
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The company had revenue of $619.80 million for the quarter, compared to analysts’ expectations of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm’s quarterly revenue was down 10.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.74 EPS. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, research analysts predict that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.
Hedge Funds Weigh In On QuidelOrtho
A number of large investors have recently modified their holdings of QDEL. Aristotle Capital Boston LLC lifted its stake in QuidelOrtho by 62.4% in the 3rd quarter. Aristotle Capital Boston LLC now owns 382,389 shares of the company’s stock worth $11,261,000 after purchasing an additional 146,956 shares in the last quarter. American Century Companies Inc. grew its position in shares of QuidelOrtho by 10.4% during the 3rd quarter. American Century Companies Inc. now owns 2,115,557 shares of the company’s stock valued at $62,303,000 after purchasing an additional 199,909 shares in the last quarter. Tejara Capital Ltd grew its position in shares of QuidelOrtho by 97.2% during the 4th quarter. Tejara Capital Ltd now owns 208,327 shares of the company’s stock valued at $5,950,000 after purchasing an additional 102,700 shares in the last quarter. Phocas Financial Corp. increased its holdings in shares of QuidelOrtho by 45.7% in the fourth quarter. Phocas Financial Corp. now owns 170,018 shares of the company’s stock worth $4,856,000 after purchasing an additional 53,353 shares during the period. Finally, Rice Hall James & Associates LLC increased its holdings in shares of QuidelOrtho by 222.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 833,791 shares of the company’s stock worth $23,813,000 after purchasing an additional 574,877 shares during the period. 99.00% of the stock is currently owned by institutional investors.
About QuidelOrtho
QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.
The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.
Featured Stories
- Five stocks we like better than QuidelOrtho
- onsemi: What the Market Gets Wrong, You Can Get Right
- Is McCormick a Steal Ahead of Game-Changing Unilever Deal?
- Qualcomm’s Investor Day Just Changed the Growth Story Forever
- JPMorgan Stands by Sky-High Broadcom Target as Shares Slide
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
